Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Development of a risk score for prediction of poor treatment outcomes among patients with multidrug-resistant tuberculosis.

Alene KA, Viney K, Gray DJ, McBryde ES, Xu Z, Clements ACA.

PLoS One. 2020 Jan 3;15(1):e0227100. doi: 10.1371/journal.pone.0227100. eCollection 2020.

2.

On the probability of strain invasion in endemic settings: Accounting for individual heterogeneity and control in multi-strain dynamics.

Meehan MT, Cope RC, McBryde ES.

J Theor Biol. 2020 Feb 21;487:110109. doi: 10.1016/j.jtbi.2019.110109. Epub 2019 Dec 6.

PMID:
31816294
3.

Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries.

Ragonnet R, Trauer JM, Geard N, Scott N, McBryde ES.

BMC Med. 2019 Nov 22;17(1):208. doi: 10.1186/s12916-019-1452-0.

4.

Strategic investment in tuberculosis control in the Republic of Bulgaria.

Doan TN, Varleva T, Zamfirova M, Tyufekchieva M, Keshelava A, Hristov K, Yaneva A, Gadzheva B, Zhang S, Irbe S, Ragonnet R, McBryde ES, Trauer JM.

Epidemiol Infect. 2019 Nov 18;147:e304. doi: 10.1017/S0950268819001857.

5.

Mathematical analysis of a Wolbachia invasive model with imperfect maternal transmission and loss of Wolbachia infection.

Adekunle AI, Meehan MT, McBryde ES.

Infect Dis Model. 2019 Oct 19;4:265-285. doi: 10.1016/j.idm.2019.10.001. eCollection 2019.

6.

Heterogeneous infectiousness in mathematical models of tuberculosis: A systematic review.

Melsew YA, Adekunle AI, Cheng AC, McBryde ES, Ragonnet R, Trauer JM.

Epidemics. 2019 Oct 17:100374. doi: 10.1016/j.epidem.2019.100374. [Epub ahead of print]

7.

Diversity of Mycobacterium tuberculosis in the Middle Fly District of Western Province, Papua New Guinea: microbead-based spoligotyping using DNA from Ziehl-Neelsen-stained microscopy preparations.

Guernier-Cambert V, Diefenbach-Elstob T, Klotoe BJ, Burgess G, Pelowa D, Dowi R, Gula B, McBryde ES, Refrégier G, Rush C, Sola C, Warner J.

Sci Rep. 2019 Oct 29;9(1):15549. doi: 10.1038/s41598-019-51892-5.

8.

Epidemiological analysis of association between lagged meteorological variables and pneumonia in wet-dry tropical North Australia, 2006-2016.

Adegboye OA, McBryde ES, Eisen DP.

J Expo Sci Environ Epidemiol. 2019 Oct 7. doi: 10.1038/s41370-019-0176-8. [Epub ahead of print]

PMID:
31591495
9.

Modelling tuberculosis control priorities: more of the same will not do.

Wejse C, Ragonnet R, McBryde ES, Trauer JM.

Lancet Glob Health. 2019 Oct;7(10):e1319. doi: 10.1016/S2214-109X(19)30286-4. No abstract available.

10.

Delay effect and burden of weather-related tuberculosis cases in Rajshahi province, Bangladesh, 2007-2012.

Kuddus MA, McBryde ES, Adegboye OA.

Sci Rep. 2019 Sep 3;9(1):12720. doi: 10.1038/s41598-019-49135-8.

11.

Profiles of tuberculosis disease activation among contacts of patients with tuberculosis.

Melsew YA, Cheng AC, McBryde ES, Denholm JT, Tay E, Ragonnet R, Trauer JM.

Eur Respir J. 2019 Oct 10;54(4). pii: 1900353. doi: 10.1183/13993003.00353-2019. Print 2019 Oct. No abstract available.

PMID:
31164436
12.

Mapping tuberculosis treatment outcomes in Ethiopia.

Alene KA, Viney K, Gray DJ, McBryde ES, Wagnew M, Clements ACA.

BMC Infect Dis. 2019 May 28;19(1):474. doi: 10.1186/s12879-019-4099-8.

13.

Health system preparedness for emerging infectious diseases: A synthesis of the literature.

Palagyi A, Marais BJ, Abimbola S, Topp SM, McBryde ES, Negin J.

Glob Public Health. 2019 Dec;14(12):1847-1868. doi: 10.1080/17441692.2019.1614645. Epub 2019 May 14.

PMID:
31084412
14.

Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.

Alene KA, Viney K, McBryde ES, Gray DJ, Melku M, Clements ACA.

Transbound Emerg Dis. 2019 Jul;66(4):1611-1618. doi: 10.1111/tbed.13188. Epub 2019 Apr 15.

PMID:
30924283
15.

The role of super-spreading events in Mycobacterium tuberculosis transmission: evidence from contact tracing.

Melsew YA, Gambhir M, Cheng AC, McBryde ES, Denholm JT, Tay EL, Trauer JM.

BMC Infect Dis. 2019 Mar 12;19(1):244. doi: 10.1186/s12879-019-3870-1.

16.

The role of geospatial hotspots in the spatial spread of tuberculosis in rural Ethiopia: a mathematical model.

Shaweno D, Trauer JM, Denholm JT, McBryde ES.

R Soc Open Sci. 2018 Sep 19;5(9):180887. doi: 10.1098/rsos.180887. eCollection 2018 Sep.

17.

Cross-Border Movement of Highly Drug-Resistant Mycobacterium tuberculosis from Papua New Guinea to Australia through Torres Strait Protected Zone, 2010-2015.

Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster J, Lavu E, Hiasihri S, McBryde ES, Moke R, Vincent S, Sintchenko V, Marais BJ, Coin LJM, Coulter C.

Emerg Infect Dis. 2019 Mar;25(3):406-415. doi: 10.3201/eid2503.181003.

18.

Global stability properties of a class of renewal epidemic models.

Meehan MT, Cocks DG, Müller J, McBryde ES.

J Math Biol. 2019 May;78(6):1713-1725. doi: 10.1007/s00285-018-01324-1. Epub 2019 Feb 9.

PMID:
30737545
19.

The Importance of Heterogeneity to the Epidemiology of Tuberculosis.

Trauer JM, Dodd PJ, Gomes MGM, Gomez GB, Houben RMGJ, McBryde ES, Melsew YA, Menzies NA, Arinaminpathy N, Shrestha S, Dowdy DW.

Clin Infect Dis. 2019 Jun 18;69(1):159-166. doi: 10.1093/cid/ciy938.

20.

Methods used in the spatial analysis of tuberculosis epidemiology: a systematic review.

Shaweno D, Karmakar M, Alene KA, Ragonnet R, Clements AC, Trauer JM, Denholm JT, McBryde ES.

BMC Med. 2018 Oct 18;16(1):193. doi: 10.1186/s12916-018-1178-4.

21.
22.

Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.

Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, Trauer JM, McBryde ES.

J Antimicrob Chemother. 2019 Jan 1;74(1):218-227. doi: 10.1093/jac/dky403.

PMID:
30295760
23.

Description of social contacts among student cases of pandemic influenza during the containment phase, Melbourne, Australia, 2009.

van Gemert C, McBryde ES, Bergeri I, Sacks-Davis R, Vally H, Spelman T, Sutton B, Hellard M.

Western Pac Surveill Response J. 2018 Oct 1;9(5 Suppl 1):27-34. doi: 10.5365/wpsar.2018.9.5.003. eCollection 2018 Winter.

24.

Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.

Doan TN, Cao P, Emeto TI, McCaw JM, McBryde ES.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01487-18. doi: 10.1128/AAC.01487-18. Print 2018 Dec.

25.

The Indo-Papuan conduit: a biosecurity challenge for Northern Australia.

Horwood PF, McBryde ES, Peniyamina D, Ritchie SA.

Aust N Z J Public Health. 2018 Oct;42(5):434-436. doi: 10.1111/1753-6405.12808. Epub 2018 Aug 8. No abstract available.

PMID:
30088687
26.

Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.

Alene KA, Clements ACA, McBryde ES, Jaramillo E, Lönnroth K, Shaweno D, Gulliver A, Viney K.

J Infect. 2018 Nov;77(5):357-367. doi: 10.1016/j.jinf.2018.07.007. Epub 2018 Jul 20.

PMID:
30036607
27.

Appropriate comparisons of tuberculosis latency structures with empiric data.

Trauer JM, Ragonnet R, McBryde ES.

Lancet Infect Dis. 2018 Jul;18(7):720-721. doi: 10.1016/S1473-3099(18)30339-6. No abstract available.

PMID:
29976525
28.

Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.

Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, Gray DJ, Xu Z, Clements ACA.

PLoS One. 2018 May 23;13(5):e0197880. doi: 10.1371/journal.pone.0197880. eCollection 2018.

29.

The influence of incomplete case ascertainment on measures of vaccine efficacy.

Wu Y, Marsh JA, McBryde ES, Snelling TL.

Vaccine. 2018 May 17;36(21):2946-2952. doi: 10.1016/j.vaccine.2018.04.046. Epub 2018 Apr 23.

PMID:
29699788
30.

Sequelae of multidrug-resistant tuberculosis: protocol for a systematic review and meta-analysis.

Alene KA, Clements ACA, McBryde ES, Jaramillo E, Lonnroth K, Shaweno D, Viney K.

BMJ Open. 2018 Feb 10;8(2):e019593. doi: 10.1136/bmjopen-2017-019593.

31.

Coupled, multi-strain epidemic models of mutating pathogens.

Meehan MT, Cocks DG, Trauer JM, McBryde ES.

Math Biosci. 2018 Feb;296:82-92. doi: 10.1016/j.mbs.2017.12.006. Epub 2017 Dec 27.

PMID:
29288702
32.

Spatiotemporal transmission and socio-climatic factors related to paediatric tuberculosis in north-western Ethiopia.

Alene KA, Viney K, McBryde ES, Clements ACA.

Geospat Health. 2017 Nov 27;12(2):575. doi: 10.4081/gh.2017.575.

33.

Molecular diagnosis of suspected tuberculosis from archived smear slides from the Balimo region, Papua New Guinea.

Guernier V, Diefenbach-Elstob T, Pelowa D, Pollard S, Burgess G, McBryde ES, Warner J.

Int J Infect Dis. 2018 Feb;67:75-81. doi: 10.1016/j.ijid.2017.12.004. Epub 2017 Dec 8.

34.

SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.

Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, Shultz TR, Biggs B, Leder K.

Intern Med J. 2017 Dec;47(12):1433-1436. doi: 10.1111/imj.13601. Erratum in: Intern Med J. 2018 Apr;48(4):488.

PMID:
29224209
35.

Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.

Doan TN, Eisen DP, Rose MT, Slack A, Stearnes G, McBryde ES.

PLoS One. 2017 Nov 28;12(11):e0188631. doi: 10.1371/journal.pone.0188631. eCollection 2017.

36.

A High Burden of Asymptomatic Gastrointestinal Infections in Traditional Communities in Papua New Guinea.

Horwood PF, Soli KW, Maure T, Naito YI, Morita A, Natsuhara K, Tadokoro K, Baba J, Odani S, Tomitsuka E, Igai K, Larkins JA, Siba PM, Pomat W, McBryde ES, Umezaki M, Greenhill AR.

Am J Trop Med Hyg. 2017 Dec;97(6):1872-1875. doi: 10.4269/ajtmh.17-0282. Epub 2017 Sep 21.

37.

A novel Bayesian geospatial method for estimating tuberculosis incidence reveals many missed TB cases in Ethiopia.

Shaweno D, Trauer JM, Denholm JT, McBryde ES.

BMC Infect Dis. 2017 Oct 2;17(1):662. doi: 10.1186/s12879-017-2759-0.

38.

Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.

Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, Gray DJ, Clements ACA, Xu Z.

BMC Infect Dis. 2017 Aug 16;17(1):573. doi: 10.1186/s12879-017-2662-8.

39.

Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching.

Trauer J, Muhi S, McBryde ES, Al Harbi SA, Arabi YM, Boyle AJ, Cartin-Ceba R, Chen W, Chen YT, Falcone M, Gajic O, Godsell J, Gong MN, Kor D, Lösche W, McAuley DF, O'Neal HR Jr, Osthoff M, Otto GP, Sossdorf M, Tsai MJ, Valerio-Rojas JC, van der Poll T, Violi F, Ware L, Widmer AF, Wiewel MA, Winning J, Eisen DP.

Crit Care Med. 2017 Nov;45(11):1871-1879. doi: 10.1097/CCM.0000000000002654.

40.

Modular programming for tuberculosis control, the "AuTuMN" platform.

Trauer JM, Ragonnet R, Doan TN, McBryde ES.

BMC Infect Dis. 2017 Aug 7;17(1):546. doi: 10.1186/s12879-017-2648-6.

41.

Optimally capturing latency dynamics in models of tuberculosis transmission.

Ragonnet R, Trauer JM, Scott N, Meehan MT, Denholm JT, McBryde ES.

Epidemics. 2017 Dec;21:39-47. doi: 10.1016/j.epidem.2017.06.002. Epub 2017 Jun 16.

42.

A user-friendly mathematical modelling web interface to assist local decision making in the fight against drug-resistant tuberculosis.

Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES.

BMC Infect Dis. 2017 May 30;17(1):374. doi: 10.1186/s12879-017-2478-6.

43.

Spatial patterns of multidrug resistant tuberculosis and relationships to socio-economic, demographic and household factors in northwest Ethiopia.

Alene KA, Viney K, McBryde ES, Clements AC.

PLoS One. 2017 Feb 9;12(2):e0171800. doi: 10.1371/journal.pone.0171800. eCollection 2017.

44.

The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains.

McBryde ES, Meehan MT, Doan TN, Ragonnet R, Marais BJ, Guernier V, Trauer JM.

Int J Infect Dis. 2017 Mar;56:14-20. doi: 10.1016/j.ijid.2017.01.031. Epub 2017 Feb 2. Review.

45.

Heterogeneity of distribution of tuberculosis in Sheka Zone, Ethiopia: drivers and temporal trends.

Shaweno D, Shaweno T, Trauer JM, Denholm JT, McBryde ES.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):79-85. doi: 10.5588/ijtld.16.0325.

PMID:
28157469
46.

Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact.

Ragonnet R, Trauer JM, McBryde ES, Houben RM, Denholm JT, Handel A, Sumner T.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):60-66. doi: 10.5588/ijtld.16.0297.

47.

AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol.

Eisen DP, Moore EM, Leder K, Lockery J, McBryde ES, McNeil JJ, Pilcher D, Wolfe R, Woods RL.

BMJ Open. 2017 Jan 20;7(1):e013636. doi: 10.1136/bmjopen-2016-013636.

48.

High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES.

BMC Infect Dis. 2017 Jan 6;17(1):36. doi: 10.1186/s12879-016-2171-1.

49.

Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.

Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC.

Trop Med Int Health. 2017 Mar;22(3):351-362. doi: 10.1111/tmi.12826. Epub 2017 Jan 6.

50.

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.

Trauer JM, Achar J, Parpieva N, Khamraev A, Denholm JT, Falzon D, Jaramillo E, Mesic A, du Cros P, McBryde ES.

BMC Med. 2016 Nov 18;14(1):187.

Supplemental Content

Loading ...
Support Center